This is the authors' abstract. We don't add key points for this paper.
Application of the AJCC-8 criteria can be expected to simplify the staging process for most DTC patients, who will now be classified as ‘younger’. It will also markedly reduce the number of patients with a substantial mortality risk (those with stages III–IV disease, where the DSS-10 is <50–70%). This new tool, together with the risk of recurrence stratification tools, should facilitate clinicians’ attempts to provide more cost-effective management of DTCs, and this improvement should also have benefits in terms of their patients’ quality of life.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lamartina et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: